Opicapone Pharmacokinetics and Effects on Catechol- O -Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa.

Peter LeWitt,Grace S Liang,C Warren Olanow,Karl D Kieburtz,Roland Jimenez,Kurt Olson,Olga Klepitskaya,Gordon Loewen

Clinical Neuropharmacology（2023）

引用 0|浏览4

暂无评分

摘要

Adding once-daily opicapone 50 mg to LD resulted in marked and extended COMT inhibition, which increased systemic exposure to LD. These changes translated into higher trough concentrations and decreased peak-to-trough fluctuations for LD.

查看译文

关键词

COMT,clinical trial,levodopa,opicapone,Parkinson disease

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要